Why the study?
Adenovirus rarely causes severe disease such as myocarditis, and treatment options are limited given adverse reactions associated with antiviral therapies.
Does IVIG improve outcomes in infants with severe adenoviral myocarditis?
Does IVIG improve outcomes in infants with severe adenoviral myocarditis?
Early treatment with IVIG may be beneficial for patients with severe adenoviral myocarditis.
Answers are grounded in this paper and cite their sources.
Raises awareness for adenovirus myocarditis in children; leaves open optimal antiviral strategies.
Adenoviruses are DNA viruses that typically cause mild self-limited disease mostly involving the respiratory tract, gastrointestinal tract or conjunctiva. Typical respiratory symptoms include fever, pharyngitis, tonsillitis, cough, and sore throat but rare associations with severe disease such as myocarditis have been reported. Current treatment options are limited to usage of intravenous immunoglobulins (IVIGs) or antiviral agent Cidofovir, however usage of the latter is limited due to reports on drug induced adverse reactions. In this case report we describe an infant with severe myocarditis in whom Adenovirus was revealed to be the identifiable cause. The infant was treated with IVIG which is believed to act as an immunomodulatory agent. The infant recovered completely. Our conclusion is that patients with myocarditis caused by adenovirus are likely to benefit from early treatment with IVIGs.
No takes yet. Share an insight, caveat, or question.
Roy et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: